Skip to main content
ABVC BIOPHARMA, INC. logo

ABVC BIOPHARMA, INC. — Investor Relations & Filings

Ticker · ABVC ISIN · US00091F1066 US Manufacturing
Filings indexed 779 across all filing types
Latest filing 2026-03-27 Regulatory Filings
Country US United States of America
Listing US ABVC

About ABVC BIOPHARMA, INC.

https://abvcpharma.com/

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes drugs and medical devices to address unmet medical needs. The company focuses on advancing a pipeline of botanical, plant-based pharmaceuticals and medical technologies sourced from research institutions. Its therapeutic areas of focus include oncology, ophthalmology, and central nervous system disorders such as major depressive disorder (MDD) and adult attention-deficit/hyperactivity disorder (ADHD). Key products in development include Vitargus®, a biodegradable vitreous substitute for eye surgery, and botanical drug candidates for MDD and ADHD. Additionally, its subsidiary, BioKey, Inc., offers contract development and manufacturing services for nutritional and pharmaceutical products.

Recent filings

Filing Released Lang Actions
POS AM - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Regulatory Filings
2026-03-27 English
ABVC BioPharma Reports 2025 Form 10-K
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the filing of the company's Annual Report (Form 10-K). It provides a summary of financial highlights and strategic updates but is clearly a news dissemination piece (indicated by 'News Details', 'Corporate News', and 'Dissemination of a Corporate News' tags) rather than the full 10-K report itself. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA). FY 2025
2026-03-03 English
10-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Annual Report FY 2025
2026-03-03 English
10-Q/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Interim / Quarterly Report Q3 2025
2026-03-03 English
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
Regulatory Filings
2026-03-03 English
ABVC BioPharma Provides Corporate and Structural Update
Regulatory Filings Classification · 95% confidence The document is a corporate press release issued by ABVC BioPharma regarding a 'Corporate and Structural Update'. It discusses business strategy, subsidiary formation (BioKey Cayman), and commercialization plans. It does not constitute a formal financial report, audit, or regulatory filing, but rather a general corporate news announcement disseminated via a news service (EQS). As it does not fit into specific categories like M&A, dividends, or director dealings, it falls under the fallback category for general regulatory and corporate announcements.
2026-02-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.